The Early Treatment Diabetic Retinopathy Study historical review and relevance to today's management of diabetic macular edema

Nidhi Relhan, Harry W Flynn

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Purpose of review To provide an historical review of the Early Treatment Diabetic Retinopathy Study (ETDRS) in the management of diabetic macular edema (DME), and to discuss its relevance to the management of DME. Recent findings The ETDRS reported that argon laser treatment is beneficial in the management of 'clinically significant' DME. The study provided guidelines for the treatment with focal and/or grid laser based on fluorescein angiographic patterns. In today's world, with the advent of optical coherence tomography, 'clinically significant' DME is now classified into center-involved DME (CI DME) and noncenter-involved DME (non-CI DME). Modified ETDRS focal/grid laser photocoagulation has been utilized in more recent clinical trials [diabetic retinopathy clinical research (DRCR) Protocols I and T] in combination with intravitreal injections. Summary The ETDRS provided outcomes data for DME, both untreated and following laser therapy. In the management of patients with DME today, the modified ETDRS focal/grid laser photocoagulation treatments remain relevant in combination with anti-vascular endothelial growth factor (anti-VEGF) therapy as ophthalmologists and their patients choose how best to treat DME. Ongoing studies in eyes with DME, nonproliferative diabetic retinopathy, and good visual acuity will help further define the place of modified ETDRS focal/grid laser in the treatment of DME.

Original languageEnglish (US)
Pages (from-to)205-212
Number of pages8
JournalCurrent Opinion in Ophthalmology
Volume28
Issue number3
DOIs
StatePublished - May 1 2017

Fingerprint

Macular Edema
Diabetic Retinopathy
Lasers
Therapeutics
Light Coagulation
Intravitreal Injections
Argon
Optical Coherence Tomography
Laser Therapy
Clinical Protocols
Fluorescein
Vascular Endothelial Growth Factor A
Visual Acuity
Outcome Assessment (Health Care)
Clinical Trials
Guidelines

Keywords

  • diabetic macular edema
  • Early Treatment Diabetic Retinopathy Study
  • focal laser photocoagulation

ASJC Scopus subject areas

  • Ophthalmology

Cite this

The Early Treatment Diabetic Retinopathy Study historical review and relevance to today's management of diabetic macular edema. / Relhan, Nidhi; Flynn, Harry W.

In: Current Opinion in Ophthalmology, Vol. 28, No. 3, 01.05.2017, p. 205-212.

Research output: Contribution to journalReview article

@article{664e5d0058884a6f8a050eeb7da9599f,
title = "The Early Treatment Diabetic Retinopathy Study historical review and relevance to today's management of diabetic macular edema",
abstract = "Purpose of review To provide an historical review of the Early Treatment Diabetic Retinopathy Study (ETDRS) in the management of diabetic macular edema (DME), and to discuss its relevance to the management of DME. Recent findings The ETDRS reported that argon laser treatment is beneficial in the management of 'clinically significant' DME. The study provided guidelines for the treatment with focal and/or grid laser based on fluorescein angiographic patterns. In today's world, with the advent of optical coherence tomography, 'clinically significant' DME is now classified into center-involved DME (CI DME) and noncenter-involved DME (non-CI DME). Modified ETDRS focal/grid laser photocoagulation has been utilized in more recent clinical trials [diabetic retinopathy clinical research (DRCR) Protocols I and T] in combination with intravitreal injections. Summary The ETDRS provided outcomes data for DME, both untreated and following laser therapy. In the management of patients with DME today, the modified ETDRS focal/grid laser photocoagulation treatments remain relevant in combination with anti-vascular endothelial growth factor (anti-VEGF) therapy as ophthalmologists and their patients choose how best to treat DME. Ongoing studies in eyes with DME, nonproliferative diabetic retinopathy, and good visual acuity will help further define the place of modified ETDRS focal/grid laser in the treatment of DME.",
keywords = "diabetic macular edema, Early Treatment Diabetic Retinopathy Study, focal laser photocoagulation",
author = "Nidhi Relhan and Flynn, {Harry W}",
year = "2017",
month = "5",
day = "1",
doi = "10.1097/ICU.0000000000000362",
language = "English (US)",
volume = "28",
pages = "205--212",
journal = "Current Opinion in Ophthalmology",
issn = "1040-8738",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - The Early Treatment Diabetic Retinopathy Study historical review and relevance to today's management of diabetic macular edema

AU - Relhan, Nidhi

AU - Flynn, Harry W

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Purpose of review To provide an historical review of the Early Treatment Diabetic Retinopathy Study (ETDRS) in the management of diabetic macular edema (DME), and to discuss its relevance to the management of DME. Recent findings The ETDRS reported that argon laser treatment is beneficial in the management of 'clinically significant' DME. The study provided guidelines for the treatment with focal and/or grid laser based on fluorescein angiographic patterns. In today's world, with the advent of optical coherence tomography, 'clinically significant' DME is now classified into center-involved DME (CI DME) and noncenter-involved DME (non-CI DME). Modified ETDRS focal/grid laser photocoagulation has been utilized in more recent clinical trials [diabetic retinopathy clinical research (DRCR) Protocols I and T] in combination with intravitreal injections. Summary The ETDRS provided outcomes data for DME, both untreated and following laser therapy. In the management of patients with DME today, the modified ETDRS focal/grid laser photocoagulation treatments remain relevant in combination with anti-vascular endothelial growth factor (anti-VEGF) therapy as ophthalmologists and their patients choose how best to treat DME. Ongoing studies in eyes with DME, nonproliferative diabetic retinopathy, and good visual acuity will help further define the place of modified ETDRS focal/grid laser in the treatment of DME.

AB - Purpose of review To provide an historical review of the Early Treatment Diabetic Retinopathy Study (ETDRS) in the management of diabetic macular edema (DME), and to discuss its relevance to the management of DME. Recent findings The ETDRS reported that argon laser treatment is beneficial in the management of 'clinically significant' DME. The study provided guidelines for the treatment with focal and/or grid laser based on fluorescein angiographic patterns. In today's world, with the advent of optical coherence tomography, 'clinically significant' DME is now classified into center-involved DME (CI DME) and noncenter-involved DME (non-CI DME). Modified ETDRS focal/grid laser photocoagulation has been utilized in more recent clinical trials [diabetic retinopathy clinical research (DRCR) Protocols I and T] in combination with intravitreal injections. Summary The ETDRS provided outcomes data for DME, both untreated and following laser therapy. In the management of patients with DME today, the modified ETDRS focal/grid laser photocoagulation treatments remain relevant in combination with anti-vascular endothelial growth factor (anti-VEGF) therapy as ophthalmologists and their patients choose how best to treat DME. Ongoing studies in eyes with DME, nonproliferative diabetic retinopathy, and good visual acuity will help further define the place of modified ETDRS focal/grid laser in the treatment of DME.

KW - diabetic macular edema

KW - Early Treatment Diabetic Retinopathy Study

KW - focal laser photocoagulation

UR - http://www.scopus.com/inward/record.url?scp=85011708784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011708784&partnerID=8YFLogxK

U2 - 10.1097/ICU.0000000000000362

DO - 10.1097/ICU.0000000000000362

M3 - Review article

VL - 28

SP - 205

EP - 212

JO - Current Opinion in Ophthalmology

JF - Current Opinion in Ophthalmology

SN - 1040-8738

IS - 3

ER -